Having agreed to buy Impact last week, Celgene Corp. could be hitting the acquisition trail again if a Wall Street Journal report proves correct and the biotech major takes full control of long-term partner and CAR-T specialist Juno Therapeutics Inc. (Also see "Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond" - Scrip, 9 January, 2018.)
Should Celgene Succumb To The Charms Of Juno?
Observers are weighing up whether it makes sense for Celgene to spend in the region of $12bn and plump for the promise of Juno's CAR-T program and whether it would be forced to abandon another promising partner in bluebird.
More from Deals
• By
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
More from Business
• By
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
• By
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
• By
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.